Literature DB >> 27660679

Contrast-enhanced ultrasonographic findings of serum amyloid A-positive hepatocellular neoplasm: Does hepatocellular adenoma arise in cirrhotic liver?

Mariko Kumagawa1, Naoki Matsumoto1, Yukinobu Watanabe1, Midori Hirayama1, Takao Miura1, Hiroshi Nakagawara1, Masahiro Ogawa1, Shunichi Matsuoka1, Mitsuhiko Moriyama1, Tadatoshi Takayama1, Masahiko Sugitani1.   

Abstract

Hepatocellular adenoma (HCA) was recently classified into four pathological subtypes. There have been few studies describing the findings of contrast-enhanced ultrasonography (CEUS) of each type. Our case concerns a 78-year-old man who had undergone routine medical check-ups for hepatitis C for 11 years. Abdominal ultrasonography showed a 28 mm, hypo-echoic mass in the segment 4 of the liver. His integrating amount of drinking was 670 kg convert into ethanol. CEUS with Sonazoid demonstrated mild uniform hypo-enhancement with inflow of microbubbles from the periphery of the tumor in the arterial phase, and heterogeneously hypo-enhancement in the post vascular phase. Because the mass increased in size within 3 mo, a well differentiated hepatocellular carcinoma was suspected, and hepatic resection was performed. Microscopic findings showed homogeneous cell proliferation with low grade atypia, infiltration of inflammatory cells, ductular reactions, fatty deposit in part, and sinusoidal dilation. Immunohistochemistry revealed geographic positive for serum amyloid A (SAA), focal positive for glutamine synthetase, diffuse and strong positive for C-reactive protein, and positive for liver-type fatty acid binding protein. These pathological features corresponded to that of an inflammatory HCA. However, we could not make a clear diagnosis, because HCAs were defined as not to arise in cirrhotic liver. Finally, this tumor was diagnosed as a SAA positive hepatocellular neoplasm.

Entities:  

Keywords:  Alcoholic cirrhosis; Contrast-enhanced ultrasonography; Hepatocellular adenoma; Serum amyloid A; Serum amyloid A-positive hepatocellular neoplasms

Year:  2016        PMID: 27660679      PMCID: PMC5026994          DOI: 10.4254/wjh.v8.i26.1110

Source DB:  PubMed          Journal:  World J Hepatol


  22 in total

1.  Characterization of focal liver lesions with contrast-specific US modes and a sulfur hexafluoride-filled microbubble contrast agent: diagnostic performance and confidence.

Authors:  Emilio Quaia; Fabrizio Calliada; Michele Bertolotto; Sandro Rossi; Lorena Garioni; Laura Rosa; Roberto Pozzi-Mucelli
Journal:  Radiology       Date:  2004-08       Impact factor: 11.105

2.  GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation.

Authors:  Jean Charles Nault; Monique Fabre; Gabrielle Couchy; Camilla Pilati; Emmanuelle Jeannot; Jeanne Tran Van Nhieu; Marie-Christine Saint-Paul; Anne De Muret; Marie-José Redon; Catherine Buffet; Sylvie Salenave; Charles Balabaud; Sophie Prevot; Philippe Labrune; Paulette Bioulac-Sage; Jean-Yves Scoazec; Philippe Chanson; Jessica Zucman-Rossi
Journal:  J Hepatol       Date:  2011-08-09       Impact factor: 25.083

3.  Contrast-enhanced sonography with SonoVue: enhancement patterns of benign focal liver lesions and correlation with dynamic gadobenate dimeglumine-enhanced MRI.

Authors:  Paolo Ricci; Andrea Laghi; Vito Cantisani; Pasquale Paolantonio; Sara Pacella; Elisa Pagliara; Federico Arduini; Valerio Pasqualini; Francesca Trippa; Marzia Filpo; Roberto Passariello
Journal:  AJR Am J Roentgenol       Date:  2005-03       Impact factor: 3.959

4.  Role of contrast-enhanced sonography in differentiation of subtypes of hepatocellular adenoma: correlation with MRI findings.

Authors:  Hervé Laumonier; Hélène Cailliez; Charles Balabaud; Laurent Possenti; Jessica Zucman-Rossi; Paulette Bioulac-Sage; Hervé Trillaud
Journal:  AJR Am J Roentgenol       Date:  2012-08       Impact factor: 3.959

5.  Hepatic tumor detection: MR imaging and conventional US versus pulse-inversion harmonic US of NC100100 during its reticuloendothelial system-specific phase.

Authors:  Flemming Forsberg; Catherine W Piccoli; Ji-Bin Liu; Nandkumar M Rawool; Daniel A Merton; Donald G Mitchell; Barry B Goldberg
Journal:  Radiology       Date:  2002-03       Impact factor: 11.105

6.  Validation of a liver adenoma classification system in a tertiary referral centre: implications for clinical practice.

Authors:  Susanna M van Aalten; Joanne Verheij; Turkan Terkivatan; Roy S Dwarkasing; Robert A de Man; Jan N M Ijzermans
Journal:  J Hepatol       Date:  2010-11-24       Impact factor: 25.083

7.  A serum amyloid A-positive hepatocellular neoplasm arising in alcoholic cirrhosis: a previously unrecognized type of inflammatory hepatocellular tumor.

Authors:  Motoko Sasaki; Norihide Yoneda; Seiko Kitamura; Yasunori Sato; Yasuni Nakanuma
Journal:  Mod Pathol       Date:  2012-07-06       Impact factor: 7.842

8.  Telangiectatic adenoma: an entity associated with increased body mass index and inflammation.

Authors:  Valérie Paradis; Axelle Champault; Maxime Ronot; Lydia Deschamps; Dominique-Charles Valla; Dominique Vidaud; Valérie Vilgrain; Jacques Belghiti; Pierre Bedossa
Journal:  Hepatology       Date:  2007-07       Impact factor: 17.425

9.  Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours.

Authors:  Sandra Rebouissou; Mohamed Amessou; Gabrielle Couchy; Karine Poussin; Sandrine Imbeaud; Camilla Pilati; Tina Izard; Charles Balabaud; Paulette Bioulac-Sage; Jessica Zucman-Rossi
Journal:  Nature       Date:  2008-11-19       Impact factor: 49.962

10.  Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas.

Authors:  Camilla Pilati; Mohamed Amessou; Michel P Bihl; Charles Balabaud; Jeanne Tran Van Nhieu; Valérie Paradis; Jean Charles Nault; Tina Izard; Paulette Bioulac-Sage; Gabrielle Couchy; Karine Poussin; Jessica Zucman-Rossi
Journal:  J Exp Med       Date:  2011-06-20       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.